← Every company
Theravance Biopharma Inc SEC Filings
What Theravance Biopharma Inc has told the SEC happened, by the 8-K items and forms it filed under: when it reported results, who joined or left, what it bought or sold, and whether its auditor or its accounts ever changed.
TBPH overview →Filings on file
139
since Oct 4, 2016
Warning signs
1
latest Sep 23, 2026
Last results
Aug 10, 2026
8-K item 2.02
Industry
Pharmaceutical Preparations
SIC 2834
Newest first
Each label is a form type or an 8-K item as filed; each row links to the filing.
| Filed | What it reports | Document |
|---|---|---|
| Sep 23, 2026 | Delisting notice or listing transferExecutive or director changeAcquisition or sale completedChange in controlMaterial agreement 8-K | Read ↗ |
| Aug 21, 2026 | Merger vote or registration DEFM14A | Read ↗ |
| Jun 2, 2025 | Acquisition or sale completedMaterial agreement 8-K | Read ↗ |
| Sep 28, 2022 | Tender offer SC TO-I | Read ↗ |
| Jul 26, 2022 | Tender offer SC TO-I | Read ↗ |
| Jul 20, 2022 | Acquisition or sale completed 8-K | Read ↗ |
| Nov 16, 2018 | Acquisition or sale completed 8-K | Read ↗ |
Source: Theravance Biopharma Inc's EDGAR filing history, the last ten years. The labels are the form types and 8-K item numbers the company filed under, not a reading of what it wrote — an item 5.02 can be a chief executive fired or a director retiring on schedule — so each row links to the filing.
More on TBPH
Company overviewEverything on TBPH in one place, with the price.Insider tradingWhat TBPH's own officers and directors buy and sell.Planned salesSales TBPH insiders have filed notice of.Executive payWhat TBPH awarded its chief executive, and what it became.PatentsWhat TBPH is filing at the patent office.